State Street AUT Europe ex UK Screened (ex Controversies and CW) Index EquityRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 8.2 | 17.5 | -7.6 | 15.3 | 4.8 | |
+/-Cat | -1.2 | 2.1 | 1.2 | 1.8 | 2.3 | |
+/-B’mrk | 0.3 | 0.3 | -0.1 | 0.3 | 0.3 | |
Category: Europe ex-UK Equity | ||||||
Category Benchmark: Morningstar DM Eur xUK TME ... |
Key Stats | ||
NAV 20/11/2024 | GBP 2.89 | |
Day Change | -0.64% | |
Morningstar Category™ | Europe ex-UK Equity | |
IA (formerly IMA) Sector | Europe Excluding UK | |
ISIN | GB00B0FR9V92 | |
Fund Size (Mil) 30/09/2022 | GBP 3600.87 | |
Share Class Size (Mil) 09/11/2021 | GBP 4425.93 | |
Max Initial Charge | - | |
Ongoing Charge 02/02/2024 | 0.12% |
Investment Objective: State Street AUT Europe ex UK Screened (ex Controversies and CW) Index Equity |
The Fund aims to replicate, as closely as possible and on a “gross of fees” basis, the return of the Europe ex UK equity market as represented by the FTSE Developed Europe ex UK ex Controversies ex CW ex Tobacco ex Thermal Coal (10%) Index, net of withholding taxes (or its recognised replacement or equivalent). |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 17/11/2006 | ||
Inception Date 17/11/2006 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
FTSE Dv Eu x UK x ConXCWXtobaXthe TR GBP | Morningstar DM Eur xUK TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for State Street AUT Europe ex UK Screened (ex Controversies and CW) Index Equity | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS Class B | Healthcare | 4.05 |
ASML Holding NV | Technology | 3.14 |
SAP SE | Technology | 3.02 |
Nestle SA | Consumer Defensive | 2.86 |
Novartis AG Registered Shares | Healthcare | 2.61 |
Increase Decrease New since last portfolio | ||
State Street AUT Europe ex UK Screened (ex Controversies and CW) Index Equity |